News|Articles|November 19, 2026

Clinical Data From Phase 3 ADEPT Studies Evaluating KarXT for Alzheimer Disease Psychosis

Author(s)Leah Kuntz
Listen
0:00 / 0:00

Key Takeaways

  • ADEPT-1 is a relapse-prevention design with a 12-week open-label lead-in before a 26-week randomized-withdrawal phase assessing time to relapse as the primary endpoint.
  • Clinician-rated psychosis measures improved over 12 weeks: NPI-C H+D decreased 12.0 points and CGI-S decreased 1.9 points among evaluable participants.
SHOW MORE

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

Bristol Myers Squibb has shared preliminary phase 3 findings of short- and long-term xanomeline and trospium chloride (KarXT) treatment from the 12-week open-label period of the ADEPT-1 study and the 52-week open-label extension (OLE) ADEPT-3 study in patients with psychosis associated with Alzheimer disease. In both studies, treatment with KarXT was associated with improvements in clinician-observed scores of hallucinations and delusions and overall disease severity. KarXT was generally well tolerated across both studies with no new safety signals identified.1

These preliminary findings represent the first disclosure of clinical data from the phase 3 ADEPT program, and were shared in an oral presentation (Abstract #OC21) at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Massachusetts.

“Hallucinations and delusions are particularly challenging aspects of Alzheimer disease and have a significant impact on people living with the disease, as well as their families and caregivers,” said Jeffrey L. Cummings, MD, ScD, Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience in the Kirk Kerkorian School of Medicine at UNLV. “These preliminary findings further our understanding of the possible impact of KarXT in this setting as we work to uncover new ways to help alleviate the added burden of psychosis for patients and families living with this devastating condition.”

The ADEPT trials remain ongoing, and data from the double-blind treatment periods in all ADEPT studies remain blinded. Participants who completed or prematurely discontinued the respective open-label period were included for analysis; those who were still ongoing at the time of data cutoff were excluded from the analysis. The findings reported are based on descriptive analyses.

About the ADEPT-1 Study

The ADEPT-1 clinical trial is a global, phase 3, randomized, double-blind, placebo-controlled relapse prevention study to evaluate the safety and efficacy of KarXT in adults with Alzheimer disease psychosis. The study includes a 12-week open-label treatment period preceding a 26-week, double-blind, randomized withdrawal period. The study is designed to evaluate the primary endpoint of time to relapse event during the 26-week double-blind period.

Among 320 participants enrolled in ADEPT-1 at the time of analysis, 273 (85.3%) completed the 12-week open-label lead-in period. During these 12 weeks, participants treated with KarXT showed improvements in hallucination and delusion scores and disease severity from baseline. A mean reduction of 12.0 points from a baseline of 14.4 (n=266) was observed on the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale. A mean reduction of 1.9 points from a baseline of 4.5 (n=267) was observed on the Clinical Global Impression-Severity (CGI-S) score. Treatment-emergent adverse events (TEAEs) occurred in 56.6% of participants, serious TEAEs in 5.0%, and TEAEs leading to discontinuation in 4.4%.

About the ADEPT-3 OLE Study

The ADEPT-3 clinical trial is a phase 3 global, 52-week, OLE rollover study for participants completing the ADEPT-1, ADEPT-2, or ADEPT-4 studies. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in adults with Alzheimer disease psychosis.

Among 401 participants enrolled in ADEPT-3 at the time of analysis, 273 (68.1%) completed the 52-week treatment period. KarXT was generally well tolerated through Week 52, with low rates of discontinuation. TEAEs occurred in 65.1% of participants, serious TEAEs in 7.7% and TEAEs leading to discontinuation in 4.7%. Improvements in symptom scores were also observed. A mean reduction of 5.1 points from an open-label baseline of 8.9 (n=270) on the NPI-C H+D scale and a mean reduction of 0.8 points from an open-label baseline of 3.4 (n=277) on the CGI-S score were observed.

“We are committed to advancing innovative science with the goal of transforming the lives of people living with some of the most complex neurological and psychiatric conditions,” said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “ADEPT-1 and ADEPT-3 are designed to answer 2 different, important questions. The open-label period of ADEPT-1 provides an initial look at how patients respond to KarXT over 12 weeks, while ADEPT-3 is evaluating the long-term safety and tolerability of KarXT over 52 weeks. We believe the improvement in hallucinations and delusion scores in ADEPT-1 and the long-term safety and tolerability findings shown in ADEPT-3 are encouraging as we await results from the double-blind periods of the ADEPT program. We look forward to sharing additional results as the program advances.”

About KarXT

The US Food and Drug Administration approval of XT in late 2024 introduced the first nondopaminergic treatment for schizophrenia. As an M1/M4-preferring muscarinic receptor agonist, this medication offers a mechanistically distinct approach to managing psychotic disorders.2

References

1. Bristol Myers Squibb presents first clinical data from two phase 3 studies in the ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease. News release. November 18, 2026. Accessed November 19, 2026. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Presents-First-Clinical-Data-from-Two-Phase-3-Studies-in-the-ADEPT-Program-Evaluating-KarXT-for-Psychosis-Associated-with-Alzheimers-Disease/default.aspx

2. Duerr HA. FDA approves Cobenfy, a first in-class agent for schizophrenia. Psychiatric Times. September 26, 2024. https://www.psychiatrictimes.com/view/fda-approves-cobenfy-for-schizophrenia



Related to this article